Skip to Content

MoviPrep (polyethylene glycol 3350 with electrolytes) Disease Interactions

There are 5 disease interactions with MoviPrep (polyethylene glycol 3350 with electrolytes):

Major

Peg Solutions (Includes MoviPrep) ↔ Gi Obstruction/Perforation

Severe Potential Hazard, High plausibility

Applies to: Gastrointestinal Obstruction, Gastrointestinal Perforation, Ulcerative Colitis

The use of polyethylene glycol (PEG) solutions is contraindicated in patients with gastrointestinal obstruction, perforation, or toxic megacolon. If gastrointestinal obstruction or perforation is suspected, appropriate studies should be performed prior to administration of these agents. Use with caution in patients with severe active ulcerative colitis. Increased activity of the gut caused by these agents could worsen these conditions.

References

  1. Raymond PL "Mallory-Weiss tear associated with polyethylene glycol electrolyte lavage solution." Gastrointest Endosc 37 (1991): 410-1
  2. "Product Information. Golytely (polyethylene glycol electrolyte solution)." Braintree, Braintree, MA.
  3. McBride MA, Vanagunas A "Esophageal perforation associated with polyethylene glycol electrolyte lavage solution." Gastrointest Endosc 39 (1993): 856-7
Moderate

Peg Electrolyte Solutions (Includes MoviPrep) ↔ Arrhythmias

Moderate Potential Hazard, Moderate plausibility

Applies to: Heart Disease

The use of ionic osmotic laxative products for bowel preparation has been associated with rare reports of serious arrhythmias. Use caution when prescribing PEG electrolyte solutions in patients at increased risk of arrhythmias (e.g., patients with a history of prolonged QT, uncontrolled arrhythmias, recent myocardial infarction, unstable angina, congestive heart failure, or cardiomyopathy). Clinical monitoring of cardiovascular status is recommended prior to, during, and after therapy.

Moderate

Peg Electrolyte Solutions (Includes MoviPrep) ↔ Impaired Gag Reflex

Moderate Potential Hazard, Moderate plausibility

Applies to: Esophageal Obstruction

Patients with impaired gag reflex, unconscious or semi-conscious patients, and patients prone to regurgitation or aspiration should be administered polyethylene glycol (PEG) electrolyte solutions cautiously. Patients experiencing severe bloating, distention or abdominal pain may need to receive PEG electrolyte solutions at a slower rate.

References

  1. "Product Information. Golytely (polyethylene glycol electrolyte solution)." Braintree, Braintree, MA.
Moderate

Peg Electrolyte Solutions (Includes MoviPrep) ↔ Renal Disease

Moderate Potential Hazard, Moderate plausibility

Applies to: Renal Dysfunction, Dehydration

Use caution when prescribing PEG electrolyte solutions to patients with impaired renal function or patients taking concomitant medications that may affect renal function. Ensure adequate hydration and consider performing baseline and post-colonoscopy laboratory tests (electrolytes, creatinine, and BUN) in these patients.

Moderate

Peg Electrolyte Solutions (Includes MoviPrep) ↔ Seizures

Moderate Potential Hazard, Moderate plausibility

Applies to: Seizures, Hyponatremia

PEG electrolyte solutions have been associated with seizure activity, and/or loss of consciousness. The seizure cases were associated with electrolyte abnormalities and low serum osmolality. Therapy with these agents should be administered cautiously in patients with a history of or predisposition to seizures or in patients with known or suspected hyponatremia.

MoviPrep (polyethylene glycol 3350 with electrolytes) drug Interactions

There are 656 drug interactions with MoviPrep (polyethylene glycol 3350 with electrolytes)

MoviPrep (polyethylene glycol 3350 with electrolytes) alcohol/food Interactions

There is 1 alcohol/food interaction with MoviPrep (polyethylene glycol 3350 with electrolytes)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide